GENMAB AS revenue breakdown overview

GENMAB AS revenue for the last year amounted to 2.21 B EUR, the most of which — 2.21 B EUR — came from its highest performing source at the moment, Antibody Therapeutics, the year earlier bringing 1.96 B EUR. The greatest contribution to the revenue figure was made by Denmark — last year it brought GENMAB AS 2.15 B EUR, and the year before that — 1.96 B EUR.